The board of the Global Fund to Fight AIDS, Tuberculosis and Malaria began a two-day meeting in Geneva on Thursday, “with one topic high on the agenda: a new funding model,” Devex’s “Development Newswire” reports. “The board will tackle aspects of a new funding model, which, according to Global Fund Director of Communications Seth Faison, ‘will change the way the Global Fund has made grants for 10 years,’” the news service writes, adding that the model, according to the International HIV/AIDS Alliance, “will see the Global Fund dropping its ’round’ grant-making process and replacing it with a ‘more flexible’ system.” In addition, “an ‘iterative dialogue process’ is also reportedly being explored,” Devex reports. “The proposed reforms seem good for the fund and its beneficiaries … [b]ut some have expressed their concerns on the funding model under consideration, specifically on the ‘historical disease application’ approach,” the news service writes (Ravelo, 9/13). According to an article on the Stop TB Partnership website, the new approach “would cap the proportion of funding available to tuberculosis (TB) projects at 16 percent,” and the proposal, “which is based on the proportion of grants awarded to TB in the past, met with strong objections from the community of people working on TB worldwide” (9/13).
The Washington Post examines how the “discovery of an almost untreatable form of tuberculosis [TB] in India has set off alarm bells around the world and helped spur a dramatic expansion of government efforts to battle the killer lung disease.” The newspaper writes, “For the past decade, a nationwide tuberculosis program involving millions of health workers and volunteers has made slow but significant progress in battling the disease in India and has been hailed as a public health success story,” but “any sense of complacency was dispelled in December when a doctor in Mumbai, Zarir Udwadia, discovered a strain of the disease that did not respond to any of the 12 frontline drugs.”
French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance “to accelerate the discovery and development of novel compounds against tuberculosis,” RTTNews reports (9/20). “According to company material, the projects will explore a compound which researchers believe has potential to treat all forms of tuberculosis, investigate another class of natural derivatives that has shown ‘impressive’ activity against tuberculosis bacteria, and identify future candidates for development among chemical compounds in Sanofi’s collection,” the Center for Global Health Policy’s “Science Speaks” blog writes (Barton, 9/20). RTTNews notes, “Sanofi, which discovered rifampicin in the early 1960s, markets several anti-tuberculosis drugs” (9/20).
PlusNews examines the recently approved grants under the Global Fund to Fight AIDS, Tuberculosis and Malaria’s Transitional Funding Mechanism (TFM), stating, “Last week, the Fund announced that 45 new grant applications, from countries such as Burundi, Malawi and Swaziland, have been approved under the TFM.” The news service notes, “Almost 25 percent of this combined total will go towards [tuberculosis (TB)], which represents a significant increase from the average 16 percent of funds allocated for TB since the Global Fund was created in 2002, according to a StopTB Partnership statement released in response” to the fund’s announcement. PlusNews notes, “Unlike regular grants, which can run for up to five years, those awarded under the TFM will be limited to two years, by which time the fund is expected to have launched its new funding model” (9/4).
Secretary of State Hillary Clinton reflects on changes in U.S. global health diplomacy since taking office in this Global Health and Diplomacy opinion piece. “America had been leading the global health fight for decades,” but “we recognized that to sustain the impact of our work, we needed to change the way we did business,” she writes. “For example, while our agencies were providing tremendous leadership in isolation, they could still do more to collaborate effectively,” she writes, adding, “[W]e weren’t doing enough to coordinate our efforts with other donors or our partner countries,” and “we weren’t building sustainable systems to eventually allow our partner countries to manage more of their own health needs.” She says, “We were unintentionally putting a ceiling on the number of lives we could save.”
“While the battle against HIV/AIDS attracts more donor funding globally than all other diseases combined, it has not diverted attention from fighting unrelated afflictions — such as malaria, measles and malnutrition — and may be improving health services overall in targeted countries, according to a study on Rwanda published” Wednesday in the American Journal of Tropical Medicine and Hygiene, an American Society of Tropical Medicine and Hygiene (ASTMH) press release reports. “A six-year investigation of health clinics in Rwanda by researchers at Brandeis University infuses fresh evidence into a long-standing debate about whether the intensive focus on HIV/AIDS, which in 2010 alone killed 1.8 million people, is undermining other health services, particularly in African countries that are at the epicenter of the pandemic,” the press release states (5/2).
“A third of the world’s population is carrying tuberculosis [TB], and the disease could become incurable if governments fail to act, the World Health Organization (WHO) has warned,” noting that a “[l]ack of funding for public health programs, the sale of inaccurate blood tests and the misuse of drugs, particularly in the private health sector, are hampering the fight against the disease and leading to drug resistance,” the Independent reports. “The rate of TB deaths had declined dramatically — by 40 percent between 1990 and 2000 — after a worldwide health campaign, which was particularly successful in China,” but “the emergence of drug-resistant strains threatens to halt progress and jeopardizes the WHO’s goal of eradicating the disease as a public health problem by 2050,” the newspaper writes, noting, “Two billion people are carriers of the TB bacillus” globally.
“[P]articipants at a symposium held last week by the U.K. Consortium on AIDS and International Development warned that [progress on HIV and tuberculosis (TB) vaccines] could be jeopardized by the recent downturn in global health funding,” BMJ reports. The journal summarizes comments made at the meeting by researchers and advocacy group representatives, who stressed that successful vaccines for HIV and TB would save millions in existing research investments and long-term treatment costs (Moszynski, 5/22).
The Global Fund to Fight AIDS, Tuberculosis and Malaria “expects to have an additional $1.6 billion to fund projects in 2012-2014, [the fund's General Manager Gabriel Jaramillo] said on Wednesday, a turnaround from a funding freeze last year,” Reuters reports (Miles, 5/9). “The new funds are a result of ‘strategic decisions made by the Board, freeing up funds that can be invested in countries where there is the most pressing demand,’ a statement by the fund said,” according to PlusNews (5/10). “The money includes funds from new donors, from traditional donors who are advancing their payments or increasing contributions and from some donors, such as China, that have offered to support projects in their own country to free up cash for more pressing needs elsewhere, Jaramillo said,” Reuters notes (5/9). “This forecast is better than expected, and it comes from the fantastic response we are getting to our transformation,” Jaramillo said, adding, “But we need more to get the job done. Countries that implement our grants are saving more and more people, but demand for services is still enormous,” according to the statement (5/9).
GlobalPost’s “Global Pulse” blog reports on a potential public-private partnership that aims to bring tuberculosis (TB) vaccine trials to the gold mines of Southern Africa, where, “[f]or every 100,000 workers …, 3,000 have tuberculosis, and many have often-fatal, drug-resistant strains of TB.” The blog writes that mining company “Anglo American announced Tuesday at the GBCHealth Conference [in New York] that it has agreed in principle to make its mines available for TB vaccine trials organized by Aeras, a non-profit that has 12 TB vaccine candidates now in various stages of research,” noting, “No formal agreement has been reached, but Anglo American’s spokesman vowed to make it happen.”